DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapidpalpitationsambulatory ECGHolter monitorevent recordersyncoperisk stratification

Palpitations and rhythm monitoring

Essential points for quick revision.

!
Escalate

Call 999 or arrange emergency admission for ongoing palpitations with syncope, significant breathlessness, chest pain, haemodynamic compromise, ventricular tachycardia or another immediately dangerous ECG finding.

Synopsis

Assess palpitations safely, identify high-risk presentations and choose monitoring that is long enough to capture the symptom-rhythm correlation.

  • Palpitations describe awareness of the heartbeat; they are a symptom, not a rhythm diagnosis.
  • Record a 12-lead ECG during symptoms whenever possible, but a normal resting ECG does not exclude an intermittent arrhythmia.
  • Match monitor duration to event frequency: 24-48 hour Holter for symptoms at least daily, longer event or patch monitoring for less frequent episodes, and an implantable loop recorder for rare but concerning events.

Key red flags

Current instability

Look for hypotension or shock, syncope, pulmonary oedema, myocardial ischaemia, severe breathlessness or altered consciousness while the rhythm is present.

Investigation priorities

01
12-lead ECGFirst step

Document rhythm and screen for conduction disease, pre-excitation, long QT, Brugada pattern, ischaemia or hypertrophy.

Management branches

acutePalpitations happening now

The patient is symptomatic during assessment.

  1. Perform ABCDE assessment, record observations and attach continuous ECG monitoring.
  2. Obtain a 12-lead ECG without delaying resuscitation; give oxygen only if hypoxaemic and obtain IV access if instability is possible.
Open full textbook Answer 2 questionsCardiology check
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom